Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Treatment with HPMA copolymer-based doxorubicin conjugate containing human immunoglobulin induces long-lasting systemic anti-tumour immunity in mice

Sirova M., Strohalm J., Subr V., Plocova D., Rossmann P., Mrkvan T., Ulbrich K., Rihova B.

. 2007 ; 56 (1) : 35-47.

Language English Country Germany

E-resources Online

NLK PubMed Central from 1982
ProQuest Central from 1997-03-01 to 1 year ago
Medline Complete (EBSCOhost) from 2000-04-01 to 1 year ago
Health & Medicine (ProQuest) from 1997-03-01 to 1 year ago
Public Health Database (ProQuest) from 1997-03-01 to 1 year ago

Linkage of doxorubicin (Dox) to a water-soluble synthetic N-(2-hydroxypropyl)methacrylamide copolymer (PHPMA) eliminates most of the systemic toxicity of the free drug. In EL-4 lymphoma-bearing C57BL/6 mice, a complete regression of pre-established tumours has been achieved upon treatment with Dox-PHPMA-HuIg conjugate. The treatment was effective using a range of regimens and dosages, ranging from 62.5 to 100% cured mice treated with a single dose of 10-20 mg of Dox eq./kg, respectively. Fractionated dosages producing lower levels of the conjugate for a prolonged time period had substantial curative capacity as well. The cured mice developed anti-tumour protection as they rejected subsequently re-transplanted original tumour. The proportion of tumour-protected mice inversely reflected the effectiveness of the primary treatment. The treatment protocol leading to 50% of cured mice produced only protected mice, while no mice treated with early treatment regimen (i.e. starting on day 1 after tumour transplantation) rejected the re-transplanted tumour. Exposure of the host to the cancer cells was a prerequisite for developing protection. The anti-tumour memory was long lasting and specific against the original tumour, as the cured mice did not reject another syngeneic tumour, melanoma B16-F10. The immunity was transferable to naive recipients in in vivo neutralization assay by spleen cells or CD8(+) lymphocytes derived from cured animals. We propose an effective treatment strategy which eradicates tumours without harming the protective immune anti-cancer responses.

000      
00000naa 2200000 a 4500
001      
bmc09004027
003      
CZ-PrNML
005      
20130214234800.0
008      
091130s2007 gw e eng||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Šírová, Milada $7 xx0127158
245    10
$a Treatment with HPMA copolymer-based doxorubicin conjugate containing human immunoglobulin induces long-lasting systemic anti-tumour immunity in mice / $c Sirova M., Strohalm J., Subr V., Plocova D., Rossmann P., Mrkvan T., Ulbrich K., Rihova B.
314    __
$a Division of Immunology and Gnotobiology, Institute of Microbiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic. sirova@biomed.cas.cz
520    9_
$a Linkage of doxorubicin (Dox) to a water-soluble synthetic N-(2-hydroxypropyl)methacrylamide copolymer (PHPMA) eliminates most of the systemic toxicity of the free drug. In EL-4 lymphoma-bearing C57BL/6 mice, a complete regression of pre-established tumours has been achieved upon treatment with Dox-PHPMA-HuIg conjugate. The treatment was effective using a range of regimens and dosages, ranging from 62.5 to 100% cured mice treated with a single dose of 10-20 mg of Dox eq./kg, respectively. Fractionated dosages producing lower levels of the conjugate for a prolonged time period had substantial curative capacity as well. The cured mice developed anti-tumour protection as they rejected subsequently re-transplanted original tumour. The proportion of tumour-protected mice inversely reflected the effectiveness of the primary treatment. The treatment protocol leading to 50% of cured mice produced only protected mice, while no mice treated with early treatment regimen (i.e. starting on day 1 after tumour transplantation) rejected the re-transplanted tumour. Exposure of the host to the cancer cells was a prerequisite for developing protection. The anti-tumour memory was long lasting and specific against the original tumour, as the cured mice did not reject another syngeneic tumour, melanoma B16-F10. The immunity was transferable to naive recipients in in vivo neutralization assay by spleen cells or CD8(+) lymphocytes derived from cured animals. We propose an effective treatment strategy which eradicates tumours without harming the protective immune anti-cancer responses.
650    _2
$a financování organizované $7 D005381
650    _2
$a zvířata $7 D000818
650    _2
$a protinádorová antibiotika $x terapeutické užití $7 D000903
650    _2
$a doxorubicin $x analogy a deriváty $x terapeutické užití $7 D004317
650    _2
$a nosiče léků $7 D004337
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé $7 D006801
650    _2
$a imunologická tolerance $7 D007108
650    _2
$a imunoglobuliny $x terapeutické užití $7 D007136
650    _2
$a lymfom T-buněčný $x farmakoterapie $x imunologie $x prevence a kontrola $7 D016399
650    _2
$a melanom experimentální $x farmakoterapie $x imunologie $x metabolismus $7 D008546
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a myši $7 D051379
650    _2
$a myši nahé $7 D008819
650    _2
$a kyseliny polymethakrylové $x terapeutické užití $7 D011109
650    _2
$a nádory kůže $x farmakoterapie $x imunologie $x metabolismus $7 D012878
650    _2
$a míra přežití $7 D015996
650    _2
$a nádorové buňky kultivované $x transplantace $7 D014407
700    1_
$a Strohalm, Jiří $7 xx0109134
700    1_
$a Šubr, Vladimír, $d 1957- $7 xx0088449
700    1_
$a Plocová, Daniela $7 xx0109133
700    1_
$a Rossmann, Pavel, $d 1933- $7 jk01102749
700    1_
$a Mrkvan, Tomáš $7 xx0062385
700    1_
$a Ulbrich, Karel, $d 1947- $7 jo2004259877
700    1_
$a Říhová, Blanka, $d 1942- $7 jo20000073671
773    0_
$w MED00001041 $t Cancer immunology and immunotherapy $g Roč. 56, č. 1 (2007), s. 35-47 $x 0340-7004
910    __
$a ABA008 $b x $y 8
990    __
$a 20091123115031 $b ABA008
991    __
$a 20130214234949 $b ABA008
999    __
$a ok $b bmc $g 699845 $s 562257
BAS    __
$a 3
BMC    __
$a 2007 $b 56 $c 1 $d 35-47 $i 0340-7004 $m Cancer immunology and immunotherapy $x MED00001041
LZP    __
$a 2009-B3/dkme

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...